Gastroscopic evaluation of the effect of a new anti-rheumatic compound, ketoprofen (19.583 R.P.), on the human gastric mucosa. A double-blind cross-over trial against acetylsalicylic acid.
The tolerance of the gastric mucosa to a new anti-inflammatory product, ketoprofen (19.583 R.P., Orudis, Profenid N.D.) was compared to the tolerance of acetylsalicylic acid in a double-blind cross-over trial using selected healthy volunteers. The effect of the medication on the gastric mucosa was examined by the use of a gastrocamera technique. The volunteers received during 2 one-week periods either acetylsalicylic acid 3 g daily or ketoprofen 100 mg daily. The sequential diagram shows that the upper barrier was crossed (preference for ketoprofen) when 10 volunteers had been analysed.
D000293:Adolescent; D000328:Adult; D000700:Analgesics / Q000633:toxicity*; D001241:Aspirin / Q000008:administration & dosage / Q000633:toxicity*; D001577:Benzophenones / Q000633:toxicity*; D002214:Capsules; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D005773:Gastroscopy; D006801:Humans; D007660:Ketoprofen / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D008875:Middle Aged
D000700:Analgesics; D001577:Benzophenones; D002214:Capsules; D007660:Ketoprofen; D001241:Aspirin